Browsing Tag

ACTAD

Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional…

Jason Junior Nov 29, 2022

Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST, a composite score of cognition…

Health

Athira Pharma Presents Study Overview and Baseline Data from ACT-AD Phase 2 Trial of Fosgonimeton in…

Jason Junior Mar 20, 2022

BOTHELL, Wash., March 20, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today…

Health

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in…

Jason Junior Nov 10, 2021

– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late…